Will Abbott Labs be successful with a combination drug? BD
What’s bad for Merck and Schering-Plough may be good for Abbott Laboratories. Yesterday’s downbeat discussion about Vytorin at a meeting of caridologists may lead doctors to look farther for alternative cholesterol treatments when statins aren’t getting the job done. The search may lead them to Abbott.
Abbott markets niacin-based drugs called Niaspan and SimCor (a combination of Niaspan and generic Zocor) as well as a fibrate drug called TriCor. Both niacins and fibrates are classes of cholesterol medicines that the New England Journal of Medicine calls suitable for use when first-line treatments (read: statins) have failed.